Jim Cramer is Neutral on Mannkind's Afrezza Inhaled Insulin

TheStreet's Jim Cramer says many people felt Mannkind's inhaled insulin drug Afrezza would fail and as a result, 28-percent of the float was short and any good news would get the stock going. On the other hand, those who believe in the drug say this is the beginning of a major move for the stock since Mannkind has already spent a "fortune" developing Afrezza. However, Cramer says he is completely neutral and sometimes it's better to admit you don't know where something is going.

At the time of publication, Cramer was long ___.